Findings

What do systematic reviews say?

10 questions · 10 findings · 1 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 30%High 7 · 70%

Anti‐CTLA4 monoclonal antibodies plus chemotherapy vs chemotherapy alone

Tumour response · people with cutaneous melanoma

Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 1.28 [0.92, 1.77]
1157 participants
Moderate

Anti‐CTLA4 monoclonal antibodies with vs without anti‐PD1 monoclonal antibodies

Tumour response · people with cutaneous melanoma

Anti‐CTLA4 monoclonal antibodies with leads to higher tumour response compared with without anti‐PD1 monoclonal antibodies (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 3.5 [2.07, 5.92]
738 participants
High

BRAF inhibitors vs chemotherapy alone

Tumour response · people with cutaneous melanoma

BRAF inhibitors leads to higher tumour response compared with chemotherapy (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 6.78 [4.84, 9.49]
925 participants
High

MEK inhibitors vs chemotherapy alone

Tumour response · people with cutaneous melanoma

MEK inhibitors leads to higher tumour response compared with chemotherapy (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 2.01 [1.35, 2.99]
496 participants
High

BRAF plus MEK inhibitors vs BRAF inhibitors

Tumour response · people with cutaneous melanoma

BRAF plus MEK inhibitors leads to higher tumour response compared with BRAF inhibitors (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 1.32 [1.2, 1.46]
1784 participants
High

Anti‐PD1 monoclonal antibodies vs chemotherapy alone

Tumour response · people with cutaneous melanoma

Anti‐PD1 monoclonal antibodies leads to higher tumour response compared with chemotherapy (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 3.42 [2.38, 4.92]
1367 participants
High

Anti‐angiogenic drugs plus chemotherapy vs chemotherapy alone

Tumour response · people with cutaneous melanoma

Anti‐angiogenic drugs plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 1.71 [0.96, 3.03]
324 participants
Moderate

Biochemotherapy vs chemotherapy alone

Tumour response · people with cutaneous melanoma

Biochemotherapy leads to higher tumour response compared with chemotherapy (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 1.36 [1.12, 1.66]
770 participants
High

Polychemotherapy vs chemotherapy alone

Tumour response · people with cutaneous melanoma

Polychemotherapy probably leads to higher tumour response compared with chemotherapy (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 1.27 [1.02, 1.58]
1885 participants
Moderate

Anti‐PD1 monoclonal antibodies vs anti‐CTLA4 monoclonal antibodies

Tumour response · people with cutaneous melanoma

Anti‐PD1 monoclonal antibodies leads to higher tumour response compared with anti‐CTLA4 monoclonal antibodies (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 2.47 [2.01, 3.04]
1465 participants
High